Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

12
results for

"Risk factors"

Article category

Keywords

Publication year

"Risk factors"

Editorials

Viral hepatitis

Citations

Citations to this article as recorded by  Crossref logo
  • Steatotic liver disease in chronic hepatitis C related hepatocellular carcinoma: Inflictor or bystander?: Correspondence to editorial on “Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after vira
    Chung-Feng Huang, Ming-Lun Yeh, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Ming-Lung Yu
    Clinical and Molecular Hepatology.2025; 31(1): e64.     CrossRef
  • Reply to comment on “Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program”
    Hung-Wei Wang, Cheng-Yuan Peng, Ming-Lung Yu
    Journal of the Formosan Medical Association.2025;[Epub]     CrossRef
  • 5,166 View
  • 41 Download
  • Crossref

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Associations between systemic inflammatory biomarkers and metabolic dysfunction associated steatotic liver disease: a cross-sectional study of NHANES 2017–2020
    Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor
    Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, Shalimar
    Journal of Clinical and Experimental Hepatology.2025; 15(5): 102559.     CrossRef
  • Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study
    Xuan-Yu Wang, Qiong Lyu, Yang-Yang Zhang, Yue Su, Hongjie Zhao, Hui-Hui Shen, Ying-Yu Xie
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Association of advanced lung cancer inflammation index with all-cause and cardiovascular mortality in metabolic dysfunction associated steatotic liver disease
    Xin Qiu, Shuang Shen, Nizhen Jiang, Yifei Feng, Guodong Yang, Donghong Lu
    Scientific Reports.2025;[Epub]     CrossRef
  • Cardiometabolic dysfunction burden and mortality outcomes in metabolic dysfunction-associated steatotic liver disease
    Ying Wen, Yu Min, Yi Lei, Zhigong Wei, Sophia Eugenia Martínez-Vázquez
    PLOS One.2025; 20(7): e0327772.     CrossRef
  • Steatotic liver disease: radiological and ultrasound point of view
    Alexey V. Borsukov, Daria Yu. Shestakova
    Consilium Medicum.2025; 27(5): 296.     CrossRef
  • Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
    Jieun Choi, Ye Rin Choi, Min Kyo Jeong, Hyun Ho Song, Jeong Seok Yu, Seol Hui Song, Jeong Ha Park, Min Ju Kim, Hyunjoon Park, Young Lim Ham, Sang Hak Han, Dong Joon Kim, Do Yup Lee, Ki Tae Suk
    Gut Microbes.2025;[Epub]     CrossRef
  • Resolution of Metabolic Dysfunction Improves Liver Health Among Chinese Children: Evidence From Two Prospective Cohorts
    Lili Yang, Menglong Li, Min Zhao, Yifei Hu, Bo Xi
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”
    Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada
    Clinical and Molecular Hepatology.2024; 30(2): 281.     CrossRef
  • Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”
    Eileen Laurel Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(4): 1033.     CrossRef
  • Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022
    Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang
    The Korean Journal of Internal Medicine.2024; 39(6): 931.     CrossRef
  • 6,166 View
  • 113 Download
  • 9 Web of Science
  • Crossref

Special Review

Steatotic liver disease

Waiting for the changes after the adoption of steatotic liver disease
Eileen L. Yoon, Dae Won Jun
Clin Mol Hepatol 2023;29(4):844-850.
Published online September 6, 2023
DOI: https://doi.org/10.3350/cmh.2023.0291
Steatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease (NAFLD). This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term “steatosis” instead of “fatty”. Herein, we will discuss the changes and continuity between the two nomenclatures, metabolic dysfunction-associated steatotic liver disease (MASLD) and NAFLD, as well as the challenges to MASLD which need to be addressed in future.

Citations

Citations to this article as recorded by  Crossref logo
  • Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease
    Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi
    Journal of Advanced Research.2026; 80: 893.     CrossRef
  • Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: nationwide cohort study with genetic risk analysis
    Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Clinical and Molecular Hepatology.2026; 32(1): 339.     CrossRef
  • Reply to: “Is liver fibrosis more advanced in MetALD than in MASLD?”
    Joo Hyun Oh, Dae Won Jun
    Journal of Hepatology.2025; 82(1): e58.     CrossRef
  • Statin use and liver-related prognosis among patients with MASLD
    Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    JHEP Reports.2025; 7(4): 101313.     CrossRef
  • Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
    Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang
    Gut and Liver.2025; 19(1): 116.     CrossRef
  • Optimal BMI cutoff for lean MASLD/MetALD and adverse hepatic outcomes in East-Asian populations
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Beom Kyung Kim, Jin-Ha Yoon
    European Journal of Internal Medicine.2025; 133: 141.     CrossRef
  • Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy
    Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen
    Cells.2025; 14(3): 221.     CrossRef
  • Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Hanne Åström, Christine Takami Lageborn, Hannes Hagström
    Expert Review of Gastroenterology & Hepatology.2025; 19(3): 273.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • A novel 11β-HSD1 inhibitor ameliorates liver fibrosis by inhibiting the notch signaling pathway and increasing NK cell population
    Ji Eun Kim, Yun Kim, Jiwon Bae, Eileen Laurel Yoon, Hyun Sung Kim, Sung Ryol Lee, Tae Hyun Yoon, Dae Won Jun
    Archives of Pharmacal Research.2025; 48(2): 166.     CrossRef
  • Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis
    Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun
    Diagnostics.2025; 15(3): 342.     CrossRef
  • Dietary Patterns Rich in Soybean Products, Vegetables, Fish, Fruits, and Miso Soup Were Inversely Associated with Fatty Liver Index: The Nagahama Study
    Yoko UEBA, Kaori IKEDA, Yasuharu TABARA, Takeo NAKAYAMA, Daisuke TANAKA, Yoshimitsu TAKAHASHI, Shinji KOSUGI, Kazuya SETOH, Takahisa KAWAGUCHI, Fumihiko MATSUDA, Nobuya INAGAKI
    Journal of Nutritional Science and Vitaminology.2025; 71(1): 25.     CrossRef
  • Identification of Novel Therapeutic Targets for MAFLD Based on Bioinformatics Analysis Combined with Mendelian Randomization
    Jialin Ren, Min Wu
    International Journal of Molecular Sciences.2025; 26(7): 3166.     CrossRef
  • Comparative Hepatic Outcomes of SGLT2i or DPP4i Compared to GLP‐1RA in CHB and T2DM Patients
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin‐Ha Yoon
    Liver International.2025;[Epub]     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Navigating the Paradox of IL‐22: Friend or Foe in Hepatic Health?
    Jianqi Qin, Weixiong Zhu, Wence Zhou
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1393.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease, Recent Revision of Terminology and Its Implications
    Hyo Young Lee, Eileen L. Yoon
    The Korean Journal of Gastroenterology.2025; 85(2): 126.     CrossRef
  • Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers
    Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim
    Clinical Gastroenterology and Hepatology.2025; 23(13): 2540.     CrossRef
  • The Role of Global Physical Capacity Score in Key Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Nicola Verrelli, Caterina Bonfiglio, Isabella Franco, Claudia Beatrice Bagnato, Dolores Stabile, Endrit Shahini, Antonella Bianco
    Journal of Clinical Medicine.2025; 14(11): 3821.     CrossRef
  • Cost-effectiveness analysis of MASLD screening using FIB-4 based two-step algorithm in the medical check-up
    Mimi Kim, Huiyul Park, Eileen L. Yoon, Ramsey Cheung, Donghee Kim, Hye-Lin Kim, Dae Won Jun
    Scientific Reports.2025;[Epub]     CrossRef
  • Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
    Gut and Liver.2025; 19(4): 479.     CrossRef
  • Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease
    Yunmi Ko, Moon Haeng Hur, Youngsu Park, Jeayeon Park, Hyunjae Shin, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
    Gut and Liver.2025; 19(5): 758.     CrossRef
  • Misclassification of Alcohol Use Disorder in MASLD and MetALD: Prevalence, Clinical Characteristics, and Outcomes
    Jun-Hyuk Lee, Sung-Ho Ahn, Jimin Park, So Young Jeon, Eileen L. Yoon, Hye Sun Lee, Dae Won Jun
    Gut and Liver.2025; 19(5): 735.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Changing from NAFLD to MASLD: Similar prognosis of unresectable extrahepatic gastrointestinal cancer under chemotherapy between NAFLD and MASLD
    Hiroyuki Suzuki, Toshimitsu Tanaka, Shotaro Yamaguchi, Keisuke Miwa, Takumi Kawaguchi
    Journal of Hepatology.2024; 80(4): e150.     CrossRef
  • Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
    Joo Hyun Oh, Dae Won Jun
    Gut and Liver.2024; 18(2): 197.     CrossRef
  • Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
    Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(2): 263.     CrossRef
  • Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
    Joo Hyun Oh, Dae Won Jun
    Clinical and Molecular Hepatology.2024; 30(2): 168.     CrossRef
  • Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2024; 30(2): 266.     CrossRef
  • Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
    Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Na
    Clinical and Molecular Hepatology.2024; 30(2): 225.     CrossRef
  • Changes in the terminology and diagnostic criteria of non-alcoholic fatty liver disease: Implications and opportunities
    Muhammed Mubarak
    World Journal of Gastrointestinal Pathophysiology.2024;[Epub]     CrossRef
  • Diagnostic performances of Fibrosis‐4 index and nonalcoholic fatty liver disease fibrosis score in metabolic dysfunction‐associated steatotic liver disease in Asian primary care clinics
    Huiyul Park, Mimi Kim, Hye‐Lin Kim, Seon Cho, Eileen L. Yoon, Dae Won Jun
    Hepatology Research.2024; 54(11): 1027.     CrossRef
  • Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology
    Piero Portincasa, Gyorgy Baffy
    European Journal of Internal Medicine.2024; 124: 35.     CrossRef
  • Revisiting the steatosis‐associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability
    Jiwon Yang, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Jonggi Choi
    Journal of Gastroenterology and Hepatology.2024; 39(10): 2112.     CrossRef
  • Barriers to care linkage and educational impact on unnecessary MASLD referrals
    Jun-Hyuk Lee, Eileen Laurel Yoon, Ju Hyun Oh, Kyunam Kim, Sang Bong Ahn, Dae Won Jun
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Gastroenterology.2024; 84(1): 1.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    The Korean Journal of Medicine.2024; 99(4): 189.     CrossRef
  • Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
    Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
    Cancers.2024; 16(18): 3161.     CrossRef
  • A New Korean Nomenclature for Steatotic Liver Disease

    Gut and Liver.2024; 18(5): 924.     CrossRef
  • A new Korean nomenclature for steatotic liver disease

    Clinical and Molecular Hepatology.2024; 30(Suppl): S214.     CrossRef
  • Combi-Elastography versus Transient Elastography for Assessing the Histological Severity of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Yun Kyu Lee, Dong Hyeon Lee, Sae Kyung Joo, Heejoon Jang, Young Ho So, Siwon Jang, Dong Ho Lee, Jeong Hwan Park, Mee Soo Chang, Won Kim
    Gut and Liver.2024; 18(6): 1048.     CrossRef
  • Establishment and characterization of mouse metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma organoids
    Sumin Kim, Nahyun Jeong, Jeayeon Park, Hyojin Noh, Ja Oh Lee, Su Jong Yu, Ja-Lok Ku
    Scientific Reports.2024;[Epub]     CrossRef
  • Metabolic Dysfunction-associated Steatotic Liver Disease–related Hepatocellular Carcinoma: Current Research Insights
    Ho Soo Chun, Minjong Lee, Tae Hun Kim
    Journal of Digestive Cancer Research.2024; 12(3): 184.     CrossRef
  • From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Li Chen
    World Journal of Hepatology.2023; 15(12): 1253.     CrossRef
  • Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
    Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon
    Clinical and Molecular Hepatology.2023; 30(1): 118.     CrossRef
  • Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
    Eileen L. Yoon, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 30(1): 126.     CrossRef
  • Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
    Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 30(1): 121.     CrossRef
  • 8,510 View
  • 190 Download
  • 42 Web of Science
  • Crossref

Editorial

Steatotic liver disease

Citations

Citations to this article as recorded by  Crossref logo
  • Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
    Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun
    Gut and Liver.2024; 18(2): 316.     CrossRef
  • Dietary inflammatory impact on NAFLD development in obese vs. lean individuals: an analysis based on NHANES 2003–2018
    Lurao Li, Xiawen Shu, Yun Yi, Chun Wang, Jianghui Li, Yang Ding, Jin Li, Ying Chang
    Lipids in Health and Disease.2024;[Epub]     CrossRef
  • Obesity and risk for liver disease: a two-sample Mendelian randomisation study
    Wen An, Jing Luo, Zhe Yu, Mengqi Li, Herui Wei, Aqian Song, Yuanpeng Mao, Hao Bian, Lingling He, Fan Xiao, Hongshan Wei
    British Journal of Nutrition.2024; 132(10): 1403.     CrossRef
  • Epigenetic Regulation in Lean Nonalcoholic Fatty Liver Disease
    Ioanna Aggeletopoulou, Maria Kalafateli, Efthymios P. Tsounis, Christos Triantos
    International Journal of Molecular Sciences.2023; 24(16): 12864.     CrossRef
  • 8,196 View
  • 109 Download
  • 4 Web of Science
  • Crossref

Letter to the Editor

Liver fibrosis, cirrhosis, and portal hypertension

Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim
Clin Mol Hepatol 2023;29(1):173-175.
Published online November 15, 2022
DOI: https://doi.org/10.3350/cmh.2022.0372

Citations

Citations to this article as recorded by  Crossref logo
  • PCDH7 as the key gene related to the co-occurrence of sarcopenia and osteoporosis
    Mingchong Liu, Yongheng Wang, Wentao Shi, Chensong Yang, Qidong Wang, Jingyao Chen, Jun Li, Bingdi Chen, Guixin Sun
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • 7,347 View
  • 48 Download
  • 1 Web of Science
  • Crossref

Original Article

Liver Transplantation

Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantation registry
Jong Man Kim, Deok Gie Kim, Jihyun Kim, Keunsung Lee, Kwang-Woong Lee, Je Ho Ryu, Bong-Wan Kim, Dong Lak Choi, Young Kyoung You, Dong-Sik Kim, Yang Won Nah, Koo Jeong Kang, Jai Young Cho, Geun Hong, Hee Chul Yu, Ju Ik Moon, Dongho Choi, Shin Hwang, Myoung Soo Kim
Clin Mol Hepatol 2021;27(3):451-462.
Published online February 2, 2021
DOI: https://doi.org/10.3350/cmh.2020.0292
Background/Aims
To analyze the incidence and risk factors of outcomes after liver transplantation (LT) in the Korean population.
Methods
This study analyzed data from the liver cohort of Korean Organ Transplantation Registry (KOTRY) who had LT between May 2014 and December 2017. Study measures included the incidence of post-LT outcomes in recipients of living donor LT (LDLT) and deceased donor LT (DDLT). Cox multivariate proportional hazards model was used to determine the potential risk factors predicting the outcomes.
Results
A total of 2,563 adult recipients with LT (LDLT, n=1,956; DDLT, n=607) were included, with mean±standard deviation age of 53.9±8.9 years, and 72.2% were male. The post-LT outcomes observed in each LDLT and DDLT recipients were death (4.0% and 14.7%), graft loss (5.0% and 16.1%), rejection (7.0% and 12.0%), renal failure (2.7% and 13.8%), new onset of diabetes (12.5% and 15.4%), and hepatocellular carcinoma (HCC) recurrence (both 6.7%). In both LDLT and DDLT recipients, the most common post-LT complications were renal dysfunction (33.6% and 51.4%), infection (26.7% and 48.4%), and surgical complication (22.5% and 23.9%). Incidence of these outcomes were generally higher among recipients of DDLT than LDLT. Multivariate analysis indicated recipient age and DDLT as significant risk factors associated with death and graft loss. DDLT and ABO incompatible transplant were prognostic factors for rejection, and HCC beyond Milan criteria at pre-transplant was a strong predictor of HCC recurrence.
Conclusions
This study is a good indicator of the post-LT prognosis in the Korean population and suggests a significant burden of post-LT complications.

Citations

Citations to this article as recorded by  Crossref logo
  • Outcomes of living-donor liver transplantation in older patients over 65 and 70 years compared to the younger recipients
    Deok-Gie Kim, Young Jin Yoo, Minyu Kang, Hwa-hee Koh, Eun-Ki Min, Jae Geun Lee, Myoung Soo Kim, Dong Jin Joo
    Asian Journal of Surgery.2026; 49(1): 76.     CrossRef
  • Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
    Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • Temporal evolution of living donor liver transplantation survival—A United Network for Organ Sharing registry study
    Christian T.J. Magyar, Zhihao Li, Laia Aceituno, Marco P.A.W. Claasen, Tommy Ivanics, Woo Jin Choi, Luckshi Rajendran, Blayne A. Sayed, Roxana Bucur, Nadia Rukavina, Nazia Selzner, Anand Ghanekar, Mark Cattral, Gonzalo Sapisochin
    American Journal of Transplantation.2025; 25(2): 406.     CrossRef
  • Impact of Chronic Hepatitis C Virus on Acute Kidney Injury After Living Donor Liver Transplantation
    Jae Hwan Kim, Kyoung-Sun Kim, Hye-Mee Kwon, Sung-Hoon Kim, In-Gu Jun, Jun-Gol Song, Gyu-Sam Hwang
    Anesthesia & Analgesia.2025; 141(3): 608.     CrossRef
  • Preoperative Factors Affecting Graft Survival After ABO-incompatible Adult Liver Transplantation
    Hyun-Jun Nam, Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dai Hoon Han, Sinyoung Kim, Kyung-A Lee, Gi Hong Choi, Dong Jin Joo, Hyun Ok Kim, Soon Sung Kwon, Myoung Soo Kim
    Transplantation.2025; 109(3): e157.     CrossRef
  • Association of primary hepatocellular carcinoma laterality with oncological outcomes for hepatic resection patients: A retrospective, multicenter, propensity score-matched study
    Okjoo Lee, Jaehong Jeong, So Kyung Yoon, Jun Chul Chung, Jongman Kim, Kwang-Woong Lee, Hyung Chul Kim
    Asian Journal of Surgery.2025; 48(4): 2241.     CrossRef
  • Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development foll
    Jongman Kim
    Clinical and Molecular Hepatology.2025; 31(2): 589.     CrossRef
  • Emergency living donor liver transplantation
    Jongman Kim
    Annals of Liver Transplantation.2025; 5(1): 27.     CrossRef
  • Safety and Therapeutic Outcomes of Adjuvant Immunotherapy With Autologous Cytokine-induced Killer Cells for Patients With Hepatocellular Carcinoma Beyond Milan Criteria After Liver Transplantation
    Geun Hong, Dong Kyu Han, Jinsoo Rhu, Suk Kyun Hong, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Jongman Kim, Jaeseok Yang, Kyung-Suk Suh
    Transplantation.2025; 109(10): e596.     CrossRef
  • Meta‐Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis
    Ana Beatriz Afonso, Carolina Morais da Silva, Paulo Nogueira, Mariana Verdelho Machado
    Alimentary Pharmacology & Therapeutics.2025; 62(8): 768.     CrossRef
  • Integrating Alpha‐Fetoprotein and Protein Induced by Vitamin K Antagonist‐II as Surveillance Tools After Liver Transplantation for Hepatocellular Carcinoma: A Novel Protocol for Early Detection of Tumor Recurrence
    Jiyoung Kim, Kwang‐Woong Lee, Jae‐Yoon Kim, Jaewon Lee, Hyun Hwa Choi, Su young Hong, Jeong‐Moo Lee, Suk Kyun Hong, YoungRok Choi, Nam‐Joon Yi, Kyung‐Suk Suh
    Clinical Transplantation.2025;[Epub]     CrossRef
  • The evaluation of inflammatory and immune composite markers for complications after deceased donor liver transplantation – a retrospective cohort study
    Zhihong Zheng, Shuman Kuang, Zipei Wang, Jin Gu, Jichang Jiang, Zhou Yu, Lijin Zhao
    Annals of Medicine.2025;[Epub]     CrossRef
  • Machine Learning–Based Selection of Resection vs Transplant and Survival in Hepatocellular Carcinoma
    Hyun Uk Kim, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
    JAMA Network Open.2025; 8(9): e2532353.     CrossRef
  • Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
    Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
    Annals of Liver Transplantation.2025; 5(2): 115.     CrossRef
  • Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
    Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
    Annals of Liver Transplantation.2025; 5(2): 107.     CrossRef
  • Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
    Seok-Hwan Kim
    Convergence Hepatology.2025; 1(1): 24.     CrossRef
  • Causes of death and associated factors with death after liver transplantation: a nationwide database study
    Junghyun Yoon, Hanjoon Kim, Dongho Choi, Boyoung Park
    HPB.2024; 26(1): 54.     CrossRef
  • Clinical impact and risk factors for cytomegalovirus infection in deceased donor liver transplantation without prophylaxis: Single center experience
    Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
    Annals of Liver Transplantation.2024; 4(1): 23.     CrossRef
  • Recurrence risk prediction models for hepatocellular carcinoma after liver transplantation
    Xu Zhang, Chi Chen, Yan Wang, Jun Xu
    Journal of Gastroenterology and Hepatology.2024; 39(11): 2272.     CrossRef
  • Chitinase-3 like-protein-1, a prognostic biomarker in patients with hepatocellular carcinoma and concomitant myosteatosis
    Chiyu He, Zhihang Hu, Zuyuan Lin, Hao Chen, Chenghao Cao, Jinyan Chen, Xudong Yang, Huigang Li, Wei Shen, Xuyong Wei, Li Zhuang, Shusen Zheng, Xiao Xu, Di Lu
    BMC Cancer.2024;[Epub]     CrossRef
  • Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study
    Tak Kyu Oh, In-Ae Song
    Annals of Surgical Treatment and Research.2024; 107(5): 245.     CrossRef
  • Effects of combined immunosuppressant and hepatitis B virus antiviral use on COVID-19 vaccination in recipients of living donor liver transplantation
    Ryunjin Lee, Jiwan Choi, Eunkyeong Lee, Jooyoung Lee, Jiye Kim, Seoon Kang, Hye-In An, Sung-Han Kim, Sung-Min Kim, Eun-Kyoung Jwa, Gil-Chun Park, Jung-Man Namgoong, Gi-Won Song, Young-In Yoon, Eunyoung Tak, Sung-Gyu Lee
    PeerJ.2024; 12: e18651.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
    Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
    American Journal of Gastroenterology.2023; 118(6): 1001.     CrossRef
  • Physical Performance Decline During the Early Posttransplantation Period Affects Survival After Living Donor Liver Transplantation
    Deok-Gie Kim, Shin Hwang, Kwang-Woong Lee, Gyu-seong Choi, Young Kyoung You, Je Ho Ryu, Bong-Wan Kim, Yang Won Nah, Dong-Sik Kim, Jai Young Cho, Koo Jeong Kang, Geun Hong, Hee Chul Yu, Man ki Ju, Suk-Won Suh, Kwan Woo Kim, Dongho Choi, Jaehong Jeong, Soo
    Transplantation.2023; 107(7): 1545.     CrossRef
  • Validation of the Model for End-Stage Liver Disease 3.0 in Korean Patients on the Liver Transplant Waiting List
    Jiwon Yang, Jung-Bin Park, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
    Clinical Gastroenterology and Hepatology.2023; 21(13): 3437.     CrossRef
  • Incidence, mortality, and risk factors associated with carbapenem‐resistant Acinetobacter baumannii bacteremia within 30 days after liver transplantation
    Eun‐Ki Min, Seung Hyuk Yim, Mun Chae Choi, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim, Deok‐Gie Kim
    Clinical Transplantation.2023;[Epub]     CrossRef
  • Risk Factors for Cytomegalovirus Infection and Its Impact on Survival after Living Donor Liver Transplantation in South Korea: A Nested Case-Control Study
    Seung Hyuk Yim, Mun Chae Choi, Deok-Gie Kim, Eun-Ki Min, Jae Geun Lee, Dong Jin Joo, Myoung Soo Kim
    Pathogens.2023; 12(4): 521.     CrossRef
  • Impact of institutional case volume of solid organ transplantation on patient outcomes and implications for healthcare policy in Korea
    Christine Kang, Ho Geol Ryu
    Korean Journal of Transplantation.2023; 37(1): 1.     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis
    Fernanda Onofrio, Katina Zheng, Cherry Xu, Shiyi Chen, Wei Xu, Mary Vyas, Katie Bingham, Keyur Patel, Leslie Lilly, Mark Cattral, Nazia Selzner, Elmar Jaeckel, Cynthia Tsien, Aliya Gulamhusein, Gideon M. Hirschfield, Mamatha Bhat
    Hepatology Communications.2023;[Epub]     CrossRef
  • Cancer Incidence in Living Liver Donors After Donor Hepatectomy
    Jongman Kim, Jae Heon Kim, Hyun Jung Kim
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • The Effect of Model for End-Stage Liver Disease 3.0 on Disparities between Patients with and without Hepatocellular Carcinoma in Korea
    Kunhee Kim, Deok-Gie Kim, Jae Geun Lee, Dong Jin Joo, Hye Won Lee
    Yonsei Medical Journal.2023; 64(11): 647.     CrossRef
  • Pretransplant Functional Status Predicts Postoperative Morbidity and Mortality after Liver Transplantation in Patients with Cirrhosis
    Myung Ji Goh, Jihye Kim, Won Hyuk Chang, Dong Hyun Sinn, Geum-Yeon Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Jong Man Kim, Wonseok Kang
    Gut and Liver.2023; 17(5): 786.     CrossRef
  • Successful liver transplantation from a donor with occlusive portal vein thrombosis
    M. S. Novruzbekov, O. D. Olisov, V. A. Gulyaev, K. N. Lutsyk, B. I. Yaremin, B. I. Kazymov, K. M. Magomedov, A. R. Akhmedov, K. F. Alekberov
    Transplantologiya. The Russian Journal of Transplantation.2023; 15(3): 334.     CrossRef
  • Evidence-based hyponatremia management in liver disease
    Ji Young Ryu, Seon Ha Baek, Sejoong Kim
    Clinical and Molecular Hepatology.2023; 29(4): 924.     CrossRef
  • Association between the early high level of serum tacrolimus and recurrence of hepatocellular carcinoma in ABO-incompatible liver transplantation
    Ji Won Han, Jong Young Choi, Eun Sun Jung, Ji Hoon Kim, Hee Sun Cho, Jae-Sung Yoo, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Ho Joong Choi, Young Kyoung You
    World Journal of Gastrointestinal Surgery.2023; 15(12): 2727.     CrossRef
  • Outcomes of living liver donors are worse than those of matched healthy controls
    Jin Yong Choi, Jae Heon Kim, Jong Man Kim, Hyun Jung Kim, Hyeong Sik Ahn, Jae-Won Joh
    Journal of Hepatology.2022; 76(3): 628.     CrossRef
  • Changes in the Deceased-Donor Trend in Korea: Establishment of Regional Trauma Centers and KODA
    Jeong-Moo Lee
    Journal of Clinical Medicine.2022; 11(5): 1239.     CrossRef
  • Healthy Spouses can be Considered as Living Liver Donors
    Okjoo Lee, Jong Man Kim, Sang Jin Kim, Jinsoo Rhu, Gyu‐Seong Choi, Jae‐Won Joh
    World Journal of Surgery.2022; 46(6): 1474.     CrossRef
  • De Novo Intrahepatic Cholangiocarcinoma After Deceased Donor Liver Transplant in an Adult Patient
    Hyung Hwan Moon, Dong Hoon Shin, Young Il Choi
    Experimental and Clinical Transplantation.2022; 20(3): 316.     CrossRef
  • Long-Term Outcomes of Laparoscopic Liver Resection for Centrally Located Hepatocellular Carcinoma
    Hyo Jun Kim, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Yeongsoo Jo, Meeyouong Kang, Yeshong Park, Eunhye Lee
    Medicina.2022; 58(6): 737.     CrossRef
  • Long-term Clinical Outcomes and Predictive Factors for Living-donor Liver Transplant Recipients With Biliary Strictures
    Ji Won Han, Jong Young Choi, Soon Kyu Lee, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Young Hoon Choi, In Seok Lee, Jung Suk Oh, Ho Jong Chun, Ho Joong Choi, Young Kyoung You
    Transplantation.2022; 106(10): 1990.     CrossRef
  • Non-Renal Risk Factors for Chronic Kidney Disease in Liver Recipients with Functionally Intact Kidneys at 1 Month
    Deok-Gie Kim, Shin Hwang, Jong Man Kim, Je Ho Ryu, Young Kyoung You, Donglak Choi, Bong-Wan Kim, Dong-Sik Kim, Yang Won Nah, Tae-Seok Kim, Jai Young Cho, Geun Hong, Jae Do Yang, Jaryung Han, Suk-Won Suh, Kwan Woo Kim, Yun Kyung Jung, Ju Ik Moon, Jun Young
    Journal of Clinical Medicine.2022; 11(14): 4203.     CrossRef
  • Evidence of nonsurgical treatment for polycystic liver disease
    Jeong-Ju Yoo, Hye In Jo, Eun-Ae Jung, Jae Seung Lee, Sang Gyune Kim, Young Seok Kim, Beom Kyung Kim
    Therapeutic Advances in Chronic Disease.2022;[Epub]     CrossRef
  • Real‐world clinical features, health‐care utilization, and economic burden in decompensated cirrhosis patients: A national database
    Hankil Lee, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2022; 37(11): 2154.     CrossRef
  • Low-grade hepatocellular carcinoma characteristics, a practical nomogram and risk stratification system: a SEER population-based study
    Dashuai Yang, Yang Su, Fangrui Zhao, Yong Hu, Kailiang Zhao, Xiangyun Xiong, Mingqiang Zhu, Junpeng Pei, Youming Ding
    Expert Review of Gastroenterology & Hepatology.2022; 16(11-12): 1115.     CrossRef
  • Low utilization of adult-to-adult LDLT in Western countries despite excellent outcomes: International multicenter analysis of the US, the UK, and Canada
    Tommy Ivanics, David Wallace, Marco P.A.W. Claasen, Madhukar S. Patel, Rushin Brahmbhatt, Chaya Shwaartz, Andreas Prachalias, Parthi Srinivasan, Wayel Jassem, Nigel Heaton, Mark S. Cattral, Nazia Selzner, Anand Ghanekar, Gabriela Morgenshtern, Neil Mehta,
    Journal of Hepatology.2022; 77(6): 1607.     CrossRef
  • Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review
    Sang Jin Kim, Jong Man Kim
    Clinical and Molecular Hepatology.2022; 28(4): 739.     CrossRef
  • Development and Validation of a Difficulty Scoring System for Laparoscopic Liver Resection to Treat Hepatolithiasis
    Yeongsoo Jo, Jai Young Cho, Ho-Seong Han, Yoo-Seok Yoon, Hae Won Lee, Jun Suh Lee, Boram Lee, Eunhye Lee, Yeshong Park, MeeYoung Kang, Junghyun Lee
    Medicina.2022; 58(12): 1847.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
    Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2022; 13(12): e00542.     CrossRef
  • Extubation in the operating room results in fewer composite mechanical ventilation-related adverse outcomes in patients after liver transplantation: a retrospective cohort study
    Yan Xu, Yiding Zuo, Li Zhou, Xuechao Hao, Xiao Xiao, Mao Ye, Lulong Bo, Chunling Jiang, Jiayin Yang
    BMC Anesthesiology.2021;[Epub]     CrossRef
  • Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
    Jong Man Kim
    Clinical and Molecular Hepatology.2021; 27(4): 562.     CrossRef
  • 13,185 View
  • 355 Download
  • 51 Web of Science
  • Crossref

Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Hepatic neoplasm

Alcohol and hepatocarcinogenesis
Makiko Taniai
Clin Mol Hepatol 2020;26(4):736-741.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0203
An excessive alcohol intake may result in fatty liver, acute/chronic hepatitis, cirrhosis, and lead to hepatocellular carcinoma (HCC). The aim of this review is to clarify the present condition and the mechanisms of alcohol-related hepatocarcinogenesis and clinical risk factors for alcohol-related HCC. There are several possible mechanisms through which alcohol may induce hepatocarcinogenesis, including the mutagenic effects of acetaldehyde toxicity through the formation of protein and DNA adducts and the production of reactive oxygen species due to the excessive hepatic deposition of iron, changes to lipid peroxidation and metabolism, inflammation and an impaired immune response and modifications to DNA methylation. Furthermore, it has been reported that alcohol accelerates liver carcinogenesis through several signaling pathways including gut-liver axis. From a clinical perspective, it is well known that alcohol interacts with other factors, such as age, gender, viral hepatitis, obesity, and diabetes leading to an increased risk of HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Leveraging cancer metabolism to translate into effective therapeutics
    Jie Xu, Linlin Guo, Yi Wang, Xiaoping Li, Ping Yi, Chunming Cheng
    Seminars in Cancer Biology.2026; 118: 44.     CrossRef
  • Liver cancer risk stratification using deep learning on nationwide longitudinal health screening data: a retrospective cohort study
    Yewon Choi, Sungmin Cho, Changdai Gu, Chungho Kim, Bomi Park, Hwiyoung Kim
    BMC Medical Informatics and Decision Making.2026;[Epub]     CrossRef
  • A Multi-Stimuli-Responsive Steroid-Based Nanosystem for Apigenin Delivery and Time-Dependent Anti-HCC Activity In Vitro
    Luwen Luo, Yaoxiao Liang, Luchang Chen, Weipeng Yang, Shenglin You, Chunying Luo, Cheng Lin
    Journal of Inorganic and Organometallic Polymers and Materials.2026;[Epub]     CrossRef
  • NADH-Activated Near-Infrared Fluorescent Probe for Efficient Screening of ADH/ALDH2 Dual Agonists for Alcohol Detoxification
    Jiwei Li, Xunfang Ding, Qilin Zhou, Lei Sun, Jin Yan, Qian Li, Hao Liu, Renshi Li, Fanchao Feng, Bo Chen, Jiangwei Tian
    Analytical Chemistry.2026;[Epub]     CrossRef
  • Global, regional, and national burden of liver cancer due to alcohol use, 1990–2021: results from the Global Burden of Disease study 2021
    Qihong Wang, Wen Jia, Jiao Liu, Qian Zhao, Zhuo Yang
    European Journal of Gastroenterology & Hepatology.2025; 37(4): 466.     CrossRef
  • Construction and validation of a diagnostic model for cholangiocarcinoma based on tumor-educated platelet RNA expression profiles
    Haiyang Hu, Jiefeng He, Haoliang Zhao
    Oncologie.2025; 27(2): 277.     CrossRef
  • Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances
    Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, Dominik Malicki, Aleksandra Piąta, Dominika Lorek, Jakub Janczura
    Medical Oncology.2025;[Epub]     CrossRef
  • Current status and perspectives of molecular mechanisms of gender difference in hepatocellular carcinoma: The tip of the iceberg?
    Zhi-Quan Xu, Shi-Qiao Luo, Zhong-Jun Wu, Rui Liao
    BioScience Trends.2025; 19(3): 266.     CrossRef
  • The epidemiology, etiology, and future prophylactic options for cancers in Mainland China
    Hongsen Chen, Jie Xu, Wenbin Liu, Xi Chen, Ping Li, Guangwen Cao
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
    Zhiqing Zhang, Hong Yang, Fei Han, Peng Guo
    Current Issues in Molecular Biology.2025; 47(6): 464.     CrossRef
  • Hepatocellular carcinoma in patients without cirrhosis
    Karina Sato-Espinoza, Mayra Valdivia-Herrera, Perapa Chotiprasidhi, Javier Diaz-Ferrer
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Gut bacteria and the host synergies promote resveratrol metabolism and induce tolerance in ALD mice
    Song-xia Zhang, Fang-fang Hu, Huan Chen, Jing Guo, Zhong-wen Xiang, Xin Ding, Meng-ling Ye, Wen-li Ye, Jun-hong Chen, Xin Wang, Wen-jing Han, Hong-hao Zhou, Wei Zhang, Yun Huang, Lie-lin Wu, Guang-hui Lian, Yao Chen
    npj Biofilms and Microbiomes.2025;[Epub]     CrossRef
  • Cis-Regulatory Alterations in FOXP4 Modulate Esophageal Cancer Susceptibility Induced by Chronic Alcohol Exposure
    Siyuan Niu, Jialing Ma, Shasha Liu, Yueping Li, Xinying Yue, Miaoxin Pan, Lina Song, Yutong Wu, Zifei Yang, Yuqian Tan, Linglong Gu, Chaolong Wang, Jiang Chang
    Cancer Research.2025; 85(14): 2591.     CrossRef
  • Identification of a novel ferroptosis-related gene signature in hepatocellular carcinoma: clinical significance, tumor microenvironment, drug sensitivity, and gene landscape analysis
    Yunzhao Hu, Chenchen Hao, Chengyuan Dong, Ping Tao, Jia Wang, Qun Lu
    Discover Oncology.2025;[Epub]     CrossRef
  • Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines
    Masaaki Mino, Eiji Kakazu, Tatsuya Kanto
    Gut and Liver.2025; 19(5): 651.     CrossRef
  • Construction of a hepatocellular carcinoma high-risk population rating scale and independent predictors' assessment
    Manyu Li, Jing Sun, Yan Wang, Jun Ma, Xiaotian Hao, Yan Liu, Cheng Zhou, Haiwei Zhou
    The American Journal of the Medical Sciences.2024; 367(3): 181.     CrossRef
  • Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction
    Karli R. LeFort, Wiramon Rungratanawanich, Byoung-Joon Song
    Cellular and Molecular Life Sciences.2024;[Epub]     CrossRef
  • Inequities in primary liver cancer in Europe: The state of play
    Loreta A. Kondili, Jeffrey V. Lazarus, Peter Jepsen, Frank Murray, Jörn M. Schattenberg, Marko Korenjak, Lucia Craxì, Maria Buti
    Journal of Hepatology.2024; 80(4): 645.     CrossRef
  • Components from Curcuma longa (Turmeric) Against Hepatobiliary Diseases Based on Gut–Liver Axis: Pharmacotherapeutic Properties and Potential Clinical Applications
    Tianhui Gao, Shuyi Wang, Zongping Zhu, Liting Lin, Yirong Luo, Meigui Lu, Wan Liao
    The American Journal of Chinese Medicine.2024; 52(02): 387.     CrossRef
  • Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC
    Yusuke Johira, Takashi Nakahara, Kenji Yamaoka, Yasutoshi Fujii, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Shiro Oka
    European Journal of Gastroenterology & Hepatology.2024; 36(4): 430.     CrossRef
  • A Review: Cytochrome P450 in Alcoholic and Non-Alcoholic Fatty Liver Disease
    Yu-Jie Jiang, Ye-Ming Cao, Yong-Bing Cao, Tian-Hua Yan, Cheng-Lin Jia, Ping He
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1511.     CrossRef
  • A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population
    Yuanlin Zou, Jicun Zhu, Caijuan Song, Tiandong Li, Keyan Wang, Jianxiang Shi, Hua Ye, Peng Wang
    Cancer Medicine.2024;[Epub]     CrossRef
  • CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma
    Feifan Yao, Suiqing Zhou, Ruizhi Zhang, Yining Chen, Wei Huang, Kai Yu, Nanmu Yang, Xiangjun Qian, Xiaofeng Tie, Jiali Xu, Yu Zhang, Tasiken Baheti, Jing Xu, Xinzheng Dai, Xiaopei Hao, Liren Zhang, Xuehao Wang, Qing Li
    Cancer Letters.2024; 593: 216935.     CrossRef
  • Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
    Byeong Geun Song, Aryoung Kim, Myung Ji Goh, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Dong Hyun Sinn
    Liver Cancer.2024; 13(5): 561.     CrossRef
  • Causal associations between platelet count, alcohol consumption, and the risk of liver hepatocellular carcinoma based on a Mendelian randomization study
    Lihua Yu, Leisheng Wang, Yuzheng Xue, Yilin Ren, Tianhao Liu, Hao Hu
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Hepatocellular Carcinoma: Prevention, Diagnosis, and Treatment
    Fei Feng, Yue Zhao
    Medical Principles and Practice.2024; 33(5): 414.     CrossRef
  • Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
    Linda Galasso, Lucia Cerrito, Valeria Maccauro, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
    International Journal of Molecular Sciences.2024; 25(13): 7191.     CrossRef
  • Meaningful nomograms based on systemic immune inflammation index predicted survival in metastatic pancreatic cancer patients receiving chemotherapy
    Yanan Sun, Jiahe Hu, Rongfang Wang, Xinlian Du, Xiaoling Zhang, Jiaoting E, Shaoyue Zheng, Yuxin Zhou, Ruishu Mou, Xuedong Li, Hanbo Zhang, Ying Xu, Yuan Liao, Wenjie Jiang, Lijia Liu, Ruitao Wang, Jiuxin Zhu, Rui Xie
    Cancer Medicine.2024;[Epub]     CrossRef
  • Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA‐C)
    Paul J. Clark, Patricia C. Valery, Simone I. Strasser, Martin Weltman, Alex Thompson, Miriam T. Levy, Barbara Leggett, Amany Zekry, Julian Rong, Marie Sinclair, Jacob George, William Sievert, Gerry MacQuillan, Edmund Tse, Amanda Nicoll, Amanda Wade, Wendy
    Drug and Alcohol Review.2024; 43(6): 1559.     CrossRef
  • Role of Epigenetic Factors in Determining the Biological Behavior and Prognosis of Hepatocellular Carcinoma
    Sami Akbulut, Zeynep Kucukakcali, Tevfik Tolga Sahin, Cemil Colak, Sezai Yilmaz
    Diagnostics.2024; 14(17): 1925.     CrossRef
  • Significance of Immune and Non-Immune Cell Stroma as a Microenvironment of Hepatocellular Carcinoma—From Inflammation to Hepatocellular Carcinoma Progression
    Jacek Baj, Magdalena Kołodziej, Joanna Kobak, Jacek Januszewski, Kinga Syty, Piero Portincasa, Alicja Forma
    International Journal of Molecular Sciences.2024; 25(19): 10233.     CrossRef
  • Epigenetic tuning of tumour-associated macrophages (TAMs): a potential approach in hepatocellular carcinoma (HCC) immunotherapy
    Israa M. Helal, Monica A. Kamal, Mostafa K. Abd El-Aziz, Hend M. El Tayebi
    Expert Reviews in Molecular Medicine.2024;[Epub]     CrossRef
  • Reply to correspondence on “Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy”
    Seren M. Gedallovich, Paul Y. Kwo
    Clinical and Molecular Hepatology.2024; 30(4): 1050.     CrossRef
  • Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application
    Lin Su, Jiawen Bu, Jiahui Yu, Mila Jin, Guanliang Meng, Xudong Zhu
    Clinical and Translational Medicine.2024;[Epub]     CrossRef
  • Application of nanotechnology in the treatment of hepatocellular carcinoma
    Liu Cai, Yanyuan Du, Hongtai Xiong, Honggang Zheng
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • ADRB2 serves as a novel biomarker and attenuates alcoholic hepatitis via the SIRT1/PGC-1α/PPARα pathway: integration of WGCNA, machine learning and experimental validation
    Li Song, Shuo Huang, Honghao Yan, Qing Ma, Qihan Luo, Jiang Qiu, Minxia Chen, Zongyuan Li, He Jiang, Yufan Chen, Fangming Chen, Yu Du, Haozhe Fu, Lisha Zhao, Kanglu Zhao, Ping Qiu
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • A nonlinear relationship between alcohol consumption and cognitive function in elderly people: a population-based study from NHANES 2011–2014
    Kaiqi Chen, Yunhua Li, Rui Yue, Zhao Jin, Shikui Cui, Xijian Zhang, Danping Zhu, Qihui Li
    Frontiers in Aging Neuroscience.2024;[Epub]     CrossRef
  • Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma
    Sha Li, Pei Xue, Xun Diao, Qi-Yu Fan, Kun Ye, Xiao-Mei Tang, Jia Liu, Zhong-Yan Huang, Qing-Hai Tang, Cheng-You Jia, Rui Xin, Zhong-Wei Lv, Ji-Bin Liu, Yu-Shui Ma, Da Fu
    Journal of Advanced Research.2023; 54: 133.     CrossRef
  • The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
    Kyoko Oura, Asahiro Morishita, Sae Hamaya, Koji Fujita, Tsutomu Masaki
    International Journal of Molecular Sciences.2023; 24(3): 2805.     CrossRef
  • Discontinuing Hepatitis Activity Reduced Hepatocellular Carcinoma Recurrence after Primary Curative Therapy
    Chern-Horng Lee, Chien-Heng Shen, Cho-Li Yen, Tzung-Hai Yen, Sen-Yung Hsieh
    Journal of Personalized Medicine.2023; 13(3): 397.     CrossRef
  • The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
    Hyunwoo Oh, Won Sohn, Yong Kyun Cho
    Clinical and Molecular Hepatology.2023; 29(Suppl): S261.     CrossRef
  • Ring finger protein 12 activates AKT signalling to promote the progression of liver cancer by interacting with EGFR
    Chengpeng Yu, Dean Rao, Tiantian Wang, Jiaqi Sheng, Enjun Lv, Long Zhang, Xun Lu, Jingjing Yu, Huifang Liang, Jia Song, Wenjie Huang
    Journal of Cellular and Molecular Medicine.2023; 27(11): 1523.     CrossRef
  • The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic status in Korea: A nationwide population-based study
    Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
    PLOS Medicine.2023; 20(6): e1004244.     CrossRef
  • Increased age, bilirubin, international normalized ratio, and creatinine score to triglyceride ratio are associated with alcohol-associated primary liver carcinoma: a single-centered retrospective study
    Xiaoqing Jia, Rong Li, Xiaoting Zhang, Tao Zhou, Dalong Sun, Na Yang, Zheng Luo
    Lipids in Health and Disease.2023;[Epub]     CrossRef
  • Association between pro-inflammatory diet and liver cancer risk: a systematic review and meta-analysis
    Kaixia Chen, Fen Yang, Xinhong Zhu, Guiyuan Qiao, Chunmei Zhang, Junxiu Tao, Xiaolian Gao, Mingzhong Xiao
    Public Health Nutrition.2023; 26(12): 2780.     CrossRef
  • Alcohol: Immunomodulatory Effects and Cancer
    Juan C. Molina, Jesús D. Guerrero-Morán, Claudia González-Espinosa
    Revista de Investigación Clínica.2023; 75(3): 129.     CrossRef
  • Epigenetics in hepatocellular carcinoma
    Ganji Purnachandra Nagaraju, Begum Dariya, Prameswari Kasa, Sujatha Peela, Bassel F. El-Rayes
    Seminars in Cancer Biology.2022; 86: 622.     CrossRef
  • Alcohol triggered bile acid disequilibrium by suppressing BSEP to sustain hepatocellular carcinoma progression
    Wenbo Chen, Qisong Zhang, Ming Ding, Jingjing Yao, Yajuan Guo, Wenxin Yan, Shaofang Yu, Qinghong Shen, Min Huang, Yaqiu Zheng, Yuefang Lin, Ying Wang, Zhongqiu Liu, Linlin Lu
    Chemico-Biological Interactions.2022; 356: 109847.     CrossRef
  • GARS is implicated in poor survival and immune infiltration of hepatocellular carcinoma
    Jinghui Wang, Bing Yang, Dingxue Wang, Rui Han, Zhanyang Bi, Lizhu Lin
    Cellular Signalling.2022; 94: 110302.     CrossRef
  • The pathogenesis of liver cancer and the therapeutic potential of bioactive substances
    Song Gao, Xingyue Jiang, Liang Wang, Shanshan Jiang, Hanyuan Luo, Yan Chen, Cheng Peng
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • The Effect of Alcohol Consumption in Unresectable Hepatocellular Carcinoma with Transarterial Chemoembolization
    Bo Sun, Lijie Zhang, Dongqiao Xiang, Qing Li, Yanqiao Ren, Yanyan Cao, Tao Sun, Weihua Zhang, Linxia Wu, Licheng Zhu, Lei Chen, Huangxuan Zhao, Chuansheng Zheng, Alessandro Granito
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Association of Diabetes Mellitus and Alcohol Abuse with Cancer: Molecular Mechanisms and Clinical Significance
    Bao Q. Lam, Rashmi Srivastava, Jason Morvant, Sharmila Shankar, Rakesh K. Srivastava
    Cells.2021; 10(11): 3077.     CrossRef
  • The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma
    Ye Xu, Qinglong Guo, Libin Wei
    Cancers.2021; 13(20): 5096.     CrossRef
  • 11,807 View
  • 230 Download
  • 55 Web of Science
  • Crossref

Review

Drug induced liver injury

Factors affecting drug-induced liver injury: antithyroid drugs as instances
Reza Heidari, Hossein Niknahad, Akram Jamshidzadeh, Narges Abdoli
Clin Mol Hepatol 2014;20(3):237-248.
Published online September 25, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.3.237

Methimazole and propylthiouracil have been used in the management of hyperthyroidism for more than half a century. However, hepatotoxicity is one of the most deleterious side effects associated with these medications. The mechanism(s) of hepatic injury induced by antithyroid agents is not fully recognized yet. Furthermore, there are no specific tools for predicting the occurrence of hepatotoxicity induced by these drugs. The purpose of this article is to give an overview on possible susceptibility factors in liver injury induced by antithyroid agents. Age, gender, metabolism characteristics, alcohol consumption, underlying diseases, immunologic mechanisms, and drug interactions are involved in enhancing antithyroid drugs-induced hepatic damage. An outline on the clinically used treatments for antithyroid drugs-induced hepatotoxicity and the potential therapeutic strategies found to be effective against this complication are also discussed.

Citations

Citations to this article as recorded by  Crossref logo
  • The antithyroid drug methimazole as an emerging aquatic contaminant: Physiological and reproductive disruption in female goldfish (Carassius auratus) and partial mitigation by thyroxine
    Hamed Abdollahpour, Milad Karimzadeh, Naghmeh Jafari Pastaki, Hosseinali Zamani
    Emerging Contaminants.2026; : 100626.     CrossRef
  • Methimazole‐induced cholestasis initially obscured by an incidental finding of a large periampullary diverticulum: A case report with reference to the updated RUCAM of 2016
    Salomon Chamay, Ari Alter, Rooshi Parikh, Shivam Khatri, Deepa Budh, Mitchell Spinnell
    JGH Open.2025;[Epub]     CrossRef
  • Propylthiouracil-induced ANCA-associated vasculitis complicated by granulocytopenia and hemophagocytosis: a case report
    Huilin Zhou, Shuchang Lai, Jinyi Chen, Yi Wang, Shasha Fu, Zongcun Chen
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Interplay between endocrine disorders and liver dysfunction: Mechanisms of damage and therapeutic approaches
    Andres M Vargas-Beltran, Samantha M Armendariz-Pineda, Froylan D Martínez-Sánchez, Carolina Martinez-Perez, Aldo Torre, Jacqueline Cordova-Gallardo
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Exploring animal models and in vitro models for liver diseases: a review
    Narendra S. Bhatt, Anilkumar K. Prajapati, Gaurang B. Shah
    Egyptian Liver Journal.2025;[Epub]     CrossRef
  • Research progress on rodent models and its mechanisms of liver injury
    Jingxin Mao, Lihong Tan, Cheng Tian, Wenxiang Wang, Hao Zhang, Zhaojing Zhu, Yan Li
    Life Sciences.2024; 337: 122343.     CrossRef
  • Protective mechanism of Paeoniae Radix Alba against chemical liver injury based on network pharmacology, molecular docking, and in vitro experiments
    Shuangqiao Liu, Xin Liu, Sijia Jiang, Min Fu, Jinxi Hu, Jiaqi Liu, Xiaoxu Fan, Yingtong Feng, Shujing Zhang, Jingxia Wang
    Journal of Traditional Chinese Medical Sciences.2024; 11(1): 55.     CrossRef
  • An Insight into the Approach Taken to Appurtenances Disorders Linked to Mitochondria
    El Bethel Lalthavel Hmar, Sujata Paul, Rofiqul Islam, Hemanta Kumar Sharma
    Biology Bulletin.2024; 51(2): 271.     CrossRef
  • Comparative Analysis of Oxidative Metabolism in Liver in Different Experimental Models of Hypothyroidism: Low Iodine Diet and Anti-Thyroid drug (Methimazole)
    Guzel Maratovna Abdullina, Feliks Khusainovich Kamilov, Valerii Nikolaevich Kozlov, Shamil Narimanovich Galimov, Nailia Timerkhatmullovna Karyagina, Irina Askhatovna Menshikova, Elvira Rafinatovna Bikmetova
    Biomedical and Pharmacology Journal.2024; 17(3): 1963.     CrossRef
  • Unusual Management of a Rare Case of Methimazole-Resistant Graves Disease
    Michael Tang, Bashar Fteiha, Shumei Meng
    JCEM Case Reports.2024;[Epub]     CrossRef
  • Vitamin D alleviates hypothyroidism associated liver dysfunction: Histological and biochemical evidence
    Seyed Hamidreza Rastegar-Moghaddam, Mahsan Akbarian, Arezoo Rajabian, Fatemeh Alipour, Alireza Ebrahimzadeh bideskan, Mahmoud Hosseini
    Heliyon.2023; 9(8): e18860.     CrossRef
  • Case report: Severe cholestatic jaundice associated with hyperthyroidism treated with methimazole
    Xiaoqiang Liu, Boming Xu, Yilin Zeng, Peizhong Chen, Yubin Wang
    Medicine.2023; 102(45): e35972.     CrossRef
  • Clinical Characteristics and Outcomes of Patients With Antithyroid Drug–Related Liver Injury
    Adeel Ahmad Khan, Fateen Ata, Afia Aziz, Hana Elamin, Aamir Shahzad, Zohaib Yousaf, Anthony Donato
    Journal of the Endocrine Society.2023;[Epub]     CrossRef
  • Advances in the Study of Related Factors of Methimazole-Induced Liver Injury
    丽芹 张
    Advances in Clinical Medicine.2022; 12(10): 9020.     CrossRef
  • Approach to the Patient: Management and the Long-term Consequences of Graves' Disease in Children
    Scott A Rivkees
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(12): 3408.     CrossRef
  • Identification of Drug-Induced Liver Injury Biomarkers from Multiple Microarrays Based on Machine Learning and Bioinformatics Analysis
    Kaiyue Wang, Lin Zhang, Lixia Li, Yi Wang, Xinqin Zhong, Chunyu Hou, Yuqi Zhang, Congying Sun, Qian Zhou, Xiaoying Wang
    International Journal of Molecular Sciences.2022; 23(19): 11945.     CrossRef
  • Comparison of long‐term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: A review of the literature
    Omar M. El Kawkgi, Douglas S. Ross, Marius N. Stan
    Clinical Endocrinology.2021; 95(1): 3.     CrossRef
  • Management of Feline Hyperthyroidism and the Need to Prevent Oxidative Stress: What Can We Learn from Human Research?
    Alessia Candellone, Vittorio Saettone, Paola Badino, Flavia Girolami, Elisabetta Radice, Domenico Bergero, Rosangela Odore, Giorgia Meineri
    Antioxidants.2021; 10(9): 1496.     CrossRef
  • Protective Effect of Natural Antioxidant Compounds on Methimazole Induced Oxidative Stress in a Feline Kidney Epithelial Cell Line (CRFK)
    Flavia Girolami, Alessia Candellone, Watanya Jarriyawattanachaikul, Giorgia Meineri, Carlo Nebbia, Paola Badino
    Veterinary Sciences.2021; 8(10): 220.     CrossRef
  • Die Schilddrüse im Alter
    Christina Tugendsam, Amir Kurtaran
    Wiener Medizinische Wochenschrift.2020; 170(15-16): 410.     CrossRef
  • Maternal Graves Disease and Abnormal CYP2D6 Genotype with Fetal Hyperthyroidism
    Christopher Spoke, Christopher Martin
    AACE Clinical Case Reports.2020; 6(4): e161.     CrossRef
  • Propylthiouracil-induced histological changes in the placenta of swiss albino mice
    Samta Tiwari, SK Pandey
    National Journal of Clinical Anatomy.2020; 9(3): 108.     CrossRef
  • Exacerbated liver injury of antithyroid drugs in endotoxin-treated mice
    Reza Heidari, Fatemeh Ahmadi, Hamid Reza Rahimi, Negar Azarpira, Massood Hosseinzadeh, Asma Najibi, Hossein Niknahad
    Drug and Chemical Toxicology.2019; 42(6): 615.     CrossRef
  • Research Progress on the Animal Models of Drug-Induced Liver Injury: Current Status and Further Perspectives
    Yingying Pan, Mingzhu Cao, Danming You, Genggeng Qin, Zhi Liu
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Boldine Supplementation Regulates Mitochondrial Function and Oxidative Stress in a Rat Model of Hepatotoxicity
    Reza Heidari, Mohammad Reza Arabnezhad, Mohammad Mehdi Ommati, Negar Azarpira, Elham Ghodsimanesh, Hossein Niknahad
    Pharmaceutical Sciences.2019; 25(1): 1.     CrossRef
  • Redox unbalance in the hyperthyroid cat: a comparison with healthy and non-thyroidal diseased cats
    Alessia Candellone, Paola Gianella, Lara Ceccarelli, Graziella Raviri, Paola Badino, Silvia Roncone, Hans S. Kooistra, Giorgia Meineri
    BMC Veterinary Research.2019;[Epub]     CrossRef
  • Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole‐induced liver injury
    Shasha Jin, Xuesong Li, Yujuan Fan, Xiaofang Fan, Yu Dai, Haishu Lin, Weimin Cai, Jialin Yang, Xiaoqiang Xiang
    Basic & Clinical Pharmacology & Toxicology.2019; 125(6): 508.     CrossRef
  • Evaluation of Antioxidant Supplementation on Redox Unbalance in Hyperthyroid Cats Treated with Methimazole: A Blinded Randomized Controlled Trial
    Alessia Candellone, Paola Badino, Paola Gianella, Flavia Girolami, Graziella Raviri, Vittorio Saettone, Giorgia Meineri
    Antioxidants.2019; 9(1): 15.     CrossRef
  • Hepatotoxicity in hyperthyroid patient after consecutive methimazole and propylthiouracil therapies
    Fernando Gomez-Peralta, Pablo Velasco-Martínez, Cristina Abreu, María Cepeda, Marta Fernández-Puente
    Endocrinology, Diabetes & Metabolism Case Reports.2018;[Epub]     CrossRef
  • Impact of cell types and culture methods on the functionality of in vitro liver systems – A review of cell systems for hepatotoxicity assessment
    Jonathan A. Kyffin, Parveen Sharma, Joseph Leedale, Helen E. Colley, Craig Murdoch, Pratibha Mistry, Steven D. Webb
    Toxicology in Vitro.2018; 48: 262.     CrossRef
  • Effect of Goiter Dispersion Formula on Serum Cytokines in Hyperthyroidism Patients with Neurologic Manifestations of Graves' Disease: A Randomized Trial on 80 Cases
    Wen-Hong Tian, Ying Wang, Rui Yang, Hai-Bing Hu
    The Journal of Alternative and Complementary Medicine.2018; 24(5): 481.     CrossRef
  • Betaine treatment protects liver through regulating mitochondrial function and counteracting oxidative stress in acute and chronic animal models of hepatic injury
    Reza Heidari, Hossein Niknahad, Ala Sadeghi, Hamidreza Mohammadi, Vahid Ghanbarinejad, Mohammad Mehdi Ommati, Arghavan Hosseini, Negar Azarpira, Forouzan Khodaei, Omid Farshad, Elaheh Rashidi, Asma Siavashpour, Asma Najibi, Asrin Ahmadi, Akram Jamshidzade
    Biomedicine & Pharmacotherapy.2018; 103: 75.     CrossRef
  • Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice
    Guihua Wang, Bo He, Wen Hu, Kexin Liu, Xiaohan Gong, Hao Kou, Yu Guo, Hui Wang
    Toxicology.2018; 408: 70.     CrossRef
  • The Opportunities of Metabolomics in Drug Safety Evaluation
    Pengcheng Wang, Amina I. Shehu, Xiaochao Ma
    Current Pharmacology Reports.2017; 3(1): 10.     CrossRef
  • Incidence of abnormal liver biochemical tests in hyperthyroidism
    Tiffany Y. Lin, Anshula O. Shekar, Ning Li, Michael W. Yeh, Sammy Saab, Mark Wilson, Angela M. Leung
    Clinical Endocrinology.2017; 86(5): 755.     CrossRef
  • Propylthiouracil-induced mitochondrial dysfunction in liver and its relevance to drug-induced hepatotoxicity
    Akram Jamshidzadeh, Hossein Niknahad, Reza Heidari, Maryam Azadbakht, Forouzan Khodaei, Mohammad Reza Arabnezhad, Omid Farshad
    Pharmaceutical Sciences.2017; 23(2): 95.     CrossRef
  • Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy
    Silvijus Abramavicius, Dzilda Velickiene, Edmundas Kadusevicius
    Medicine.2017; 96(39): e8159.     CrossRef
  • Kupffer cell‐mediated exacerbation of methimazole‐induced acute liver injury in rats
    Sho Akai, Yasuaki Uematsu, Koichi Tsuneyama, Shingo Oda, Tsuyoshi Yokoi
    Journal of Applied Toxicology.2016; 36(5): 702.     CrossRef
  • Effect of Thiol-reducing Agents and Antioxidants on Sulfasalazine-induced Hepatic Injury in Normotermic Recirculating Isolated Perfused Rat Liver
    Reza Heidari, Neda Esmailie, Negar Azarpira, Asma Najibi, Hossein Niknahad
    Toxicological Research.2016; 32(2): 133.     CrossRef
  • Drug-induced liver injury caused by iodine-131
    Chei Won Kim, Ji Sun Park, Se Hwan Oh, Jae-Hyung Park, Hyun-Ik Shim, Jae Woong Yoon, Jin Seok Park, Seong Bin Hong, Jun Mi Kim, Trong Binh Le, Jin Woo Lee
    Clinical and Molecular Hepatology.2016; 22(2): 272.     CrossRef
  • Hyperthyroidism Improves the Pathological Condition of Nonalcoholic Steatohepatitis: A Case of Nonalcoholic Steatohepatitis with Graves' Disease
    Teruki Miyake, Bunzo Matsuura, Shinya Furukawa, Yasuhiko Todo, Shin Yamamoto, Osamu Yoshida, Yusuke Imai, Takao Watanabe, Yasunori Yamamoto, Masashi Hirooka, Yoshio Tokumoto, Teru Kumagi, Masanori Abe, Hirotaka Seike, Shozo Miyauchi, Yoichi Hiasa
    Internal Medicine.2016; 55(15): 2019.     CrossRef
  • Paradoxical effect of methimazole on liver mitochondria: In vitro and in vivo
    Hossein Niknahad, Akram Jamshidzadeh, Reza Heidari, Zeynab Hosseini, Keivan Mobini, Forouzan Khodaei, Mohammad Mehdi Ommati, Narges Abdoli, Nahid Keshavarz, Mandana Bazyari, Asma Najibi
    Toxicology Letters.2016; 259: 108.     CrossRef
  • Serial Changes of Liver Function Tests before and during Methimazole Treatment in Thyrotoxic Patients
    Dan Alexandru Niculescu, Roxana Dusceac, Simona Andreea Galoiu, Cristina Ana-Maria Capatina, Catalina Poiana
    Endocrine Practice.2016; 22(8): 974.     CrossRef
  • The Postulated Hepatotoxic Metabolite of Methimazole Causes Mitochondrial Dysfunction and Energy Metabolism Disturbances in Liver
    Hossein Niknahad, Akram Jamshidzadeh, Reza Heidari, Narges Abdoli, Mohammad Mehdi Ommati, Faezeh Jafari, Mahdi Zarei, Behnam Asadi
    Pharmaceutical Sciences.2016; 22(4): 217.     CrossRef
  • Carbonyl Traps as Potential Protective Agents against Methimazole‑Induced Liver Injury
    Reza Heidari, Hossein Niknahad, Akram Jamshidzadeh, Negar Azarpira, Mandana Bazyari, Asma Najibi
    Journal of Biochemical and Molecular Toxicology.2015; 29(4): 173.     CrossRef
  • Propylthiouracil-Induced Liver Injury in Mice and the Protective Role of Taurine
    Raziyeh Karamikhah, Akram Jamshidzadeh, Negar Azarpira, Arastoo Saeidi, Reza Heidari
    Pharmaceutical Sciences.2015; 21(2): 94.     CrossRef
  • Sulfasalazine-Induced Hepatic Injury in an Ex Vivo Model of Isolated Perfused Rat Liver and the Protective Role of Taurine
    Reza Heidari, Nazanin Sadeghi, Negar Azarpira, Hossein Niknahad
    Pharmaceutical Sciences.2015; 21(4): 211.     CrossRef
  • Factors Predicting Abnormal Liver Function Tests Induced by Graves’ Disease Alone
    Ruiguo Zhang, Xun Tian, Lan Qin, Xiaoer Wei, Junqi Wang, Jie Shen
    Medicine.2015; 94(19): e839.     CrossRef
  • Cellular and Molecular Aspects of Drug-Induced Liver Toxicity: Recent Prominent Mechanisms
    Pinar Erkekoglu
    MOJ Toxicology.2015;[Epub]     CrossRef
  • 26,722 View
  • 356 Download
  • 43 Web of Science
  • Crossref
Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Predictive factors that influence the survival rates in liver cirrhosis patients with spontaneous bacterial peritonitis
Pei Chuan Tsung, Soo Hyung Ryu, In Hye Cha, Hee Won Cho, Jin Nam Kim, You Sun Kim, Jeong Seop Moon
Clin Mol Hepatol 2013;19(2):131-139.
Published online June 27, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.2.131
Background/Aims

Spontaneous bacterial peritonitis (SBP) has been known to greatly influence the survival rate of patients with liver cirrhosis. However, the factors that affect the survival rate in patients with SBP need to be clarified.

Methods

This study enrolled 95 liver cirrhosis patients diagnosed with SBP. The laboratory findings of their serum and ascitic fluid were examined and the characteristics of the isolated microorganisms in their peritoneal fluid were analyzed.

Results

The proportion of patients with culture-positive SBP was 41.1%, and 47 microorganisms were isolated from the ascitic fluid. The proportions of cultured bacteria that were Gram negative and Gram positive were 57.4% and 40.4%, respectively. The proportions of Escherichia coli, Klebsiella species, and Streptococcus species were 25.5%, 19.1%, and 19.1%, respectively. Enterococcus species represented 12.8% of the microorganisms cultured. The overall survival rates at 6, 12, and 24 months were 44.5%, 37.4%, and 32.2%, respectively. There was no relationship between the bacterial factors and the survival rate in SBP. Multivariate analysis revealed that the presence of hepatocellular carcinoma (HCC; P=0.001), higher serum bilirubin levels (≥3 mg/dL, P=0.002), a prolonged serum prothrombin time (i.e., international normalized ratio >2.3, P<0.001), renal dysfunction (creatinine >1.3 mg/dL, P<0.001), and lower glucose levels in the ascitic fluid (<50 mg/dL, P<0.001) were independent predictive factors of overall survival rate.

Conclusions

HCC, higher serum bilirubin levels, a prolonged serum prothrombin time, renal dysfunction, and lower ascitic glucose levels are associated with higher mortality rates in cirrhotic patients with SBP.

Citations

Citations to this article as recorded by  Crossref logo
  • Von Willebrand factor and VITRO score as useful markers predict spontaneous bacterial peritonitis with and without hepatorenal syndrome in Egyptian cirrhotic patients
    Helal Mohammed Salem, Hanan Ahmed Elbassat, Amal Said El Bendary, Shimaa Mahmoud El_Sharawy
    Tanta Medical Journal.2025; 53(1): 114.     CrossRef
  • Spontaneous Bacterial Peritonitis as a Precipitating Factor of Hepatic Encephalopathy and Its Outcomes During Hospital Admission
    Muntazir Mahdi, Maqsood Ahmad
    Indus Journal of Bioscience Research.2025; 3(3): 419.     CrossRef
  • Bacterial profile, drug resistance pattern, clinical and laboratory predictors of ascites infection in cirrhosis patients
    Abubeker Shemsu Helil, Shambel Araya Haile, Yohannis Birhanu, Hailemichael Desalegn, Daniel Melese Desalegn, Rozina Ambachew Geremew, Zenebe Gebreyohannes, Awad Mohammed, Daniel Dejene Wondimagegnehu, Gonfa Ayana, Anteneh Mehari Tizazu, Kassu Desta
    BMC Infectious Diseases.2024;[Epub]     CrossRef
  • Initial treatment response and short-term mortality of spontaneous bacterial peritonitis in cirrhotic patients with hepatocellular carcinoma
    Chang Hun Lee, Hye Jin Kang, Song Yi Yu, Seung Young Seo, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, In Hee Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Clinical features, microbial spectrum, and antibiotic susceptibility patterns of spontaneous bacterial peritonitis in cirrhotic patients
    Xin Zhang, Xiao-Xi Li, Jin-Wen Song, Xiao-Chang Zhang, Cheng Zhen, Jing-Feng Bi, Fu-Yu Lu, Su-Ming Chen, Dan Dan Huo, Peng Zhao, Da-Wei Zhang, Bo Tu, Chun-Mei Bao, Fu-Sheng Wang, Lei Huang
    Digestive and Liver Disease.2023; 55(11): 1554.     CrossRef
  • Spontan bakteriyel peritonitli hastalarda hastane içi mortaliteyi etkileyen faktörler
    Ramazan GÖKDEMİR, Müge USTAOĞLU, Hasan ERUZUN, Ahmet BEKTAŞ
    Akademik Gastroenteroloji Dergisi.2022; 20(3): 150.     CrossRef
  • Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases
    Jianwei Liu, Hui Xue, Shilei Bai, Jie Wang, Yue Zhang, Liu Liu, Lei Zhang, Zhao Yang, KuiWang
    Heliyon.2022; 8(11): e11248.     CrossRef
  • Recurrent and Treatment-Unresponsive Spontaneous Bacterial Peritonitis Worsens survival in Decompensated Liver Cirrhosis
    Edmondo Falleti, Sara Cmet, Anna R. Cussigh, Elena Salvador, Davide Bitetto, Ezio Fornasiere, Elisa Fumolo, Carlo Fabris, Pierluigi Toniutto
    Journal of Clinical and Experimental Hepatology.2021; 11(3): 334.     CrossRef
  • Predictors of Short-Term Mortality Following First Episode of Spontaneous Bacterial Peritonitis in Hospitalized Cirrhotic Patients
    Abdel-Naser Elzouki, Abdelrahman Hamad, Hussam Almasri, Mohamed Ata, Anas Ashour, Muftah Othman, Ahmad Badi, Mehdi Errayes, Muhammad Zahid, Mohammed Danjuma
    Cureus.2021;[Epub]     CrossRef
  • Development and Validation of a Prognostic Model for One-year Survival of Cirrhosis Patients with First-ever Spontaneous Bacterial Peritonitis
    Rui-Rui Wang, Hong-Qiu Gu, Ying-Ying Wei, Jin-Xiang Yang, Yi-Xin Hou, Hui-Min Liu, Zhi-Yun Yang, Xian-Bo Wang, Yu-Yong Jiang
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • An Epidemiological Meta-Analysis on the Worldwide Prevalence, Resistance, and Outcomes of Spontaneous Bacterial Peritonitis in Cirrhosis
    Phoebe Wen Lin Tay, Jieling Xiao, Darren Jun Hao Tan, Cheng Ng, Yan Nerng Lye, Wen Hui Lim, Vanessa Xin Yi Teo, Ryan Rui Yang Heng, Marcus Wei Xuan Yeow, Lionel Hon Wai Lum, Eunice Xiang Xuan Tan, Guan Sen Kew, Guan Huei Lee, Mark D. Muthiah
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • The pattern of microbial flora in Spontaneous bacterial peritonitis in Cirrhotic patients
    Sehrish Jahan Asif, Murataza Gondal, Shahida Parveen, Sumera Mushtaq, Shumaila Awan, Tassawar Hussain
    Journal of Rawalpindi Medical College.2020; : 62.     CrossRef
  • Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis
    Bo Tu, Yue-Ning Zhang, Jing-Feng Bi, Zhe Xu, Peng Zhao, Lei Shi, Xin Zhang, Guang Yang, En-Qiang Qin
    World Journal of Gastroenterology.2020; 26(29): 4316.     CrossRef
  • Short- and long-term predictors of spontaneous bacterial peritonitis in Singapore
    YJ Wong, RC Kalki, KW Lin, R Kumar, J Tan, EK Teo, JW Li, TL Ang
    Singapore Medical Journal.2020; 61(8): 419.     CrossRef
  • Follow-up Creatinine Level Is an Important Predictive Factor of In-hospital Mortality in Cirrhotic Patients with Spontaneous Bacterial Peritonitis
    Baek Gyu Jun, Woong Cheul Lee, Jae Young Jang, Soung Won Jeong, Young Don Kim, Gab Jin Cheon, Yun Nah Lee, Sang Gyune Kim, Young Seok Kim, Young Sin Cho, Sae Hwan Lee, Hong Soo Kim
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Spontaneous bacterial and fungal peritonitis in patients with liver cirrhosis: A literature review
    Toru Shizuma
    World Journal of Hepatology.2018; 10(2): 254.     CrossRef
  • The first episode of spontaneous bacterial peritonitis is a threat event in children with end-stage liver disease
    Sandra M.G. Vieira, Fernando P. Schwengber, Melina Melere, Marília R. Ceza, Melina Souza, Carlos O. Kieling
    European Journal of Gastroenterology & Hepatology.2018; 30(3): 323.     CrossRef
  • Predicting mortality in patients with spontaneous bacterial peritonitis using routine inflammatory and biochemical markers
    Raim Iliaz, Tahsin Ozpolat, Bulent Baran, Kadir Demir, Sabahattin Kaymakoglu, Fatih Besisik, Filiz Akyuz
    European Journal of Gastroenterology & Hepatology.2018; 30(7): 786.     CrossRef
  • Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis
    Nian-zhi Ning, Tao Li, Ju-ling Zhang, Fen Qu, Jie Huang, Xiong Liu, Zhan Li, Wei Geng, Jun-liang Fu, Wang Huan, Shu-yong Zhang, Chun-mei Bao, Hui Wang
    BMC Infectious Diseases.2018;[Epub]     CrossRef
  • Spontaneous Bacterial Peritonitis
    Do Seon Song
    The Korean Journal of Gastroenterology.2018; 72(2): 56.     CrossRef
  • Bacterascites: A study of clinical features, microbiological findings, and clinical significance
    Rosalie C. Oey, Henk R. van Buuren, David M. de Jong, Nicole S. Erler, Robert A. de Man
    Liver International.2018; 38(12): 2199.     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications

    Clinical and Molecular Hepatology.2018; 24(3): 230.     CrossRef
  • Rifaximin has the potential to prevent complications of cirrhosis
    Steven L. Flamm, Kevin D. Mullen, Zeev Heimanson, Arun J. Sanyal
    Therapeutic Advances in Gastroenterology.2018;[Epub]     CrossRef
  • Prognosis of Spontaneous Bacterial Peritonitis in Hepatocellular Carcinoma Patients
    Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Assessment of calprotectin in ascitic fluid as a marker for spontaneous bacterial peritonitis diagnosis in cirrhotic patients
    Fayrouz O. Selim, Nahawand A. El-Deeb, Hesham A. Farrag, Azza M. Ahmed
    The Egyptian Journal of Internal Medicine.2018; 30(4): 223.     CrossRef
  • Treatment for cirrhotic ascites
    Hideto Kawaratani, Hiroshi Fukui, Hitoshi Yoshiji
    Hepatology Research.2017; 47(2): 166.     CrossRef
  • Prognostic impact of peritonitis in hemodialysis patients: A national-wide longitudinal study in Taiwan
    Yueh-An Lu, Kun-Hua Tu, Cheng-Chia Lee, Patricia W. Wu, Chee-Jen Chang, Ya-Chung Tian, Chih-Wei Yang, Pao-Hsien Chu, Tatsuo Shimosawa
    PLOS ONE.2017; 12(3): e0173710.     CrossRef
  • Prognostic factors of liver cirrhosis mortality after a first episode of spontaneous bacterial peritonitis. A multicenter study
    Luigi Melcarne, Julia Sopeña, Francisco José Martínez-Cerezo, Mercedes Vergara, Mireia Miquel, Jordi Sánchez-Delgado, Blai Dalmau, Salvador Machlab, Dustin Portilla, Yonaisy Gonzàlez-Padrón, Mónica Real Álvarez, Chantal Carpintero, Meritxell Casas
    Revista Española de Enfermedades Digestivas.2017;[Epub]     CrossRef
  • Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis
    Tary A. Salman, Ahmed M. Edrees, Hala H. El-Said, Osama L. El-Abd, Gasser I. El-Azab
    European Journal of Gastroenterology & Hepatology.2016; 28(7): 777.     CrossRef
  • Predictive model of mortality in patients with spontaneous bacterial peritonitis
    M. Poca, E. Alvarado‐Tapias, M. Concepción, C. Pérez‐Cameo, N. Cañete, I. Gich, C. Romero, M. Casas, E. Román, L. Castells, V. Vargas, J. A. Carrión, C. Guarner, G. Soriano
    Alimentary Pharmacology & Therapeutics.2016; 44(6): 629.     CrossRef
  • Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective
    Marco Fiore, Sebastiano Leone
    World Journal of Gastroenterology.2016; 22(34): 7742.     CrossRef
  • The Negative Prognostic Impact of a First Ever Episode of Spontaneous Bacterial Peritonitis in Cirrhosis and Ascites
    Greta Ra, Cynthia Tsien, Eberhard L. Renner, Florence Suet-Hing Wong
    Journal of Clinical Gastroenterology.2015; 49(10): 858.     CrossRef


  • Experimental and Clinical Transplantation.2015;[Epub]     CrossRef
  • Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites
    Philipp Schwabl, Theresa Bucsics, Kathrin Soucek, Mattias Mandorfer, Simona Bota, Alexander Blacky, Alexander M. Hirschl, Arnulf Ferlitsch, Michael Trauner, Markus Peck‐Radosavljevic, Thomas Reiberger
    Liver International.2015; 35(9): 2121.     CrossRef
  • 12,162 View
  • 104 Download
  • Crossref
Natural history of gastric varices and risk factors for bleeding
Choong Hyeon Lee, M.D., Joon Hyoek Lee, M.D., Ph.D., Yong Sung Choi, M.D., Seung Woon Paik, M.D., Dong Hyun Sinn, M.D., Choon Young Lee, M.D., Kwang Cheol Koh, M.D., Geum-Youn Gwak, M.D., Moon Seok Choi, M.D., Byung Chul Yoo, M.D.
Korean J Hepatol 2008;14(3):331-341.
Published online September 30, 2008
DOI: https://doi.org/10.3350/kjhep.2008.14.3.331
Background/Aims
Gastric varices (GV) are one of the most serious complications of portal hypertension, but there is limited information on the clinical course of GV in Korea. The aim of this study was to elucidate the natural history of GV bleeding in Korean patients. Methods: Of 604 patients with GV diagnosed between May 1995 and May 2005 at the Samsung Medical Center, 237 patients without a history of variceal bleeding or previous intervention for varices were investigated. The cumulative incidence rates of GV bleeding, long-term survival rates, and risk factors for GV bleeding were evaluated. Results: The cumulative incidence rates of GV bleeding were 4.8%, 19.9%, and 23.2% at 1, 3, and 5 years after diagnosis, respectively. The overall survival rates were 88.6%, 53.2%, and 37.2% at 1, 5, and 10 years. In the univariate analysis, fundal varices, large (F3) GV, red color sign, and poor liver function (Child-Pugh class B or C) were significant risk factors for GV bleeding. In the multivariate analysis, large GV (hazard ratio 2.49) and poor liver function (hazard ratio 3.95) were the independent risk factors. Conclusions: GV bleeding was more frequent in patients with fundal varices than in patients with type 1 gastroesophageal varices, and large GV and poor liver function were risk factors for GV bleeding. Close observation and prophylaxis for variceal bleeding might be warranted in high-risk patients. (Korean J Hepatol 2008;14:331-341)

Citations

Citations to this article as recorded by  Crossref logo
  • Endohepatology: Evolving Indications, Challenges, Unmet Needs and Opportunities
    Akash Roy, Mithun Sharma, Anand V. Kulkarni, Sundeep Lakhtakia, Aniruddha Pratap Singh, Rakesh Kalapala, Gregory G. Ginsberg, D.Nageshwar Reddy, K. Rajender Reddy
    Gastro Hep Advances.2026; 5(2): 100838.     CrossRef
  • Effectiveness of retrograde transvenous obliteration for primary prophylaxis of gastric variceal bleeding
    Nisha Howarth, Yashasavi Sachar, Derek HW Little, David Peck, Amol Mujoomdar, Derek W Cool, David Hocking, Anouar Teriaky, Karim Qumosani, Qasim Khan, Ephraim Tang, Anton Skaro, Juan Pablo Arab, Mayur Brahmania
    Canadian Liver Journal.2025; 8(1): 79.     CrossRef
  • Endoscopic treatment for gastroesophageal varices in patients with cirrhosis: a survey comparing between developed and developing countries
    Wenhui Zhang, Ning Kang, Yanling Wang, Fulong Zhang, Jianbo Xue, Enqiang Linghu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Endoscopic Treatment and Prevention of Acute Variceal Hemorrhage
    Youngdae Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(1): 5.     CrossRef
  • Hepatic Venous Pressure Gradient Predicts Further Decompensation in Cirrhosis Patients with Acute Esophageal Variceal Bleeding
    Manas Vaishnav, Sagnik Biswas, Abhinav Anand, Piyush Pathak, Shekhar Swaroop, Arnav Aggarwal, Umang Arora, Anshuman Elhence, Shivanand Gamanagatti, Amit Goel, Ramesh Kumar, Shalimar
    Diagnostics.2023; 13(14): 2385.     CrossRef
  • How to Approach a Patient With Gastric Varices
    Amit Maydeo, Gaurav Patil
    Gastroenterology.2022; 162(3): 689.     CrossRef
  • Variceal Hemorrhage: Decompression, Obliteration, or Both?
    Benjamin J. McCafferty, Husamedin El Khudari, Aliaksei Salei, Andrew J. Gunn
    Digestive Disease Interventions.2022; 06(02): 094.     CrossRef
  • Safety and efficacy of EUS-guided coil and glue injection for the primary prophylaxis of gastric variceal hemorrhage
    Abdul Kouanda, Kenneth Binmoeller, Christopher Hamerski, Andrew Nett, Jona Bernabe, Janak Shah, Yasser Bhat, Rabindra Watson
    Gastrointestinal Endoscopy.2021; 94(2): 291.     CrossRef
  • Conventional versus selective balloon-occluded retrograde transvenous obliteration of gastric varices
    Ramy Ahmed, Hiro Kiyosue, Hiromu Mori, Samy Abdelaziz, Moustafa Othman, Sherif Abdel-Aal, Miyuki Maruno, Shunro Matsumoto
    Egyptian Journal of Radiology and Nuclear Medicine.2020;[Epub]     CrossRef
  • KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

    Clinical and Molecular Hepatology.2020; 26(2): 83.     CrossRef
  • Update on management of gastric varices
    Louisa J Vine, Mohsan Subhani, Juan G Acevedo
    World Journal of Hepatology.2019; 11(3): 250.     CrossRef
  • Endoscopic Cyanoacrylate Glue Injection in Management of Gastric Variceal Bleeding: US Tertiary Care Center Experience
    Subhash Chandra, Adrian Holm, Rami G. El Abiad, Henning Gerke
    Journal of Clinical and Experimental Hepatology.2018; 8(2): 181.     CrossRef
  • Plug-Assisted Retrograde Transvenous Obliteration for the Treatment of Gastric Variceal Hemorrhage
    Min-Yung Chang, Man-Deuk Kim, Taehwan Kim, Wonseon Shin, Minwoo Shin, Gyoung Min Kim, Jong Yun Won, Sung Il Park, Do Yun Lee
    Korean Journal of Radiology.2016; 17(2): 230.     CrossRef
  • Clinical features and outcomes of gastric variceal bleeding: retrospective Korean multicenter data
    Moon Young Kim, Soon Ho Um, Soon Koo Baik, Yeon Seok Seo, Soo Young Park, Jung Il Lee, Jin Woo Lee, Gab Jin Cheon, Joo Hyun Sohn, Tae Yeob Kim, Young Suk Lim, Tae Hyo Kim, Tae Hee Lee, Sung Jae Park, Seung Ha Park, Jin Dong Kim, Sang Young Han, Chang Soo
    Clinical and Molecular Hepatology.2013; 19(1): 36.     CrossRef
  • Iatrogenic fatal bleeding of ruptured gastric varix mimicking submucosal mass: An autopsy case
    Hye‐Jong Song, Jung‐Sik Kwak, Sang‐Han Lee
    Basic and Applied Pathology.2009; 2(1): 44.     CrossRef
  • 6,023 View
  • 87 Download
  • Crossref
Establishment of Individual Prediction Model According to Risk Factorsfor Development of Hepatocellular Carcinoma in Korea : Establishment of Individual Prediction Model for Hepatocellular Carcinoma
Jae Youn Cheong, M.D., Kwang-Hyub Han, M.D., Dong Kee Kim, Ph.D.*, Sang Hoon Ahn, M.D., Ki Jun Song, M.S.*, Yong Han Paik, M.D., Chang Hwan Choi, M.D., Hyun Woong Lee, M.D., Young Soo Park, M.D., Chae Yoon Chon, M.D., and Young Myoung Moon, M.D.,
Korean J Hepatol 2001;7(4):449-458.
Background
/ Aim : We identified risk factors for hepatocellular carcinoma(HCC)through a nine-year follow-up study, ending last year, of 4,339 patients with chronic liver disease. The aim of this study was to establish an individual prediction model according to risk factors for the development of HCC. Methods : We studied a total of 1994 patients who had regular check-ups from January 1990 to December 1998. We analyzed the risk factors and established the individual prediction model to predict the risk rate for HCC using logistic regression analysis. We applied the model to patients who were enrolled over the next two years. Results : 90(9.05%) out of 994 patients developed HCC during a mean of 33 months of follow-up. The risk index for individual patients was made by considering the relative risk level of statistically significant risk factors. From 1999 to 2000, 480 patients were newly enrolled and divided into a low risk group(less than 5% probability), an intermediate risk group(5% to 10% probability), and a high risk group(more than 10% probability). According to this classification, 1 of 191 patients in the low risk group(0.523%), 5 of 176 patients intermediate risk group(2.84%), and 21 of 113 patients in the high risk group(18.6%) were diagnosed with HCC. Conclusion : We confirmed the reliability of the newly established individual prediction model for the screening of HCC. This model may help screening programs to be done effectively by focusing on high risk groups for HCC. (Korean J Hepatol 2001;7 :449- 458)
  • 2,992 View
  • 19 Download
Risk Factors of Morbidity and Mortality Following Surgical Resection for Hepatocellular Carcinoma
Wan Wook Kim, M.D., Kwang-Woong Lee, M.D., Sung Ho Choi, M.D., Jin Seok Heo, M.D., Yong Il Kim, M.D., Sung Ju Kim, M.D., Dae Sung Lee, M.D., Hwan Hyo Lee, M.D., Seung Woon Paik, M.D.1, Kwang Cheol Koh, M.D.1, Joon Hyoek Lee, M.D.1, Moon Seok Choi, M.D.1 , Byung Chul Yoo, M.D.1 and Jae Won Joh, M.D.
Korean J Hepatol 2004;10(1):51-61.
Background/Aims
Recently, mortality following surgical resection for hepatocelluar carcinoma has been reduced significantly. Morbidity, however, is still significant. This study evaluated the risk factors leading to morbidity and mortality. Methods: 510 patients who had a hepatic resection form Nov. 1994 to Dec. 2001 were included. The patient demographics showed a mean age of 51.6 years with a male to female ratio of 4:1. The HBsAg was positive in 76.0% and the anti-HCV was positive in 8.2%. The mean tumor size was 5.2 cm, 26.2% of patients had preoperative transcatheter arterial embolization (TAE), and 8.7% had preoperative percutaneous transhepatic portal embolization (PTPE). Limited resection was performed in 259 cases (50.7%), and major resection was conducted in 251 cases (49.1%). Risk factors included age, sex, laboratory findings (liver function test, prothrombin time, albumin, glucose, α-fetoprotein, ICG test), preoperative TAE, PTPE, operation type, operation time, intraoperative transfusion, tumor size, and cirrhosis.
Results
The morbidity was 10.5% (54 cases). Operative death occurred in 5 cases (1.0%). Hospital death, including operative death, occurred in 6 cases (1.2%). Five cases were associated with hepatic failure and 1 case was associated with aspiration pneumonia accompanying hepatic failure. Transfusion (P=0.002), glucose (P=0.002), and prothrombin time (P=0.038) were significantly related to morbidity. Age (P=0.028), glucose (P=0.011), and TAE (P=0.046) were significantly related to mortality. Conclusions: Intraoperative transfusion, which is mainly related to intraoperative bleeding, should be reduced if possible to decrease morbidity. Diabetes mellitus patients and the elderly need careful perioperative management.(Korean J Hepatol 2004;10:51-61)
  • 3,775 View
  • 20 Download